Replimune Group, Inc. (NASDAQ:REPL) Chairman Sells $245,394.16 in Stock

Replimune Group, Inc. (NASDAQ:REPL) Chairman Philip Astley-Sparke sold 37,928 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $6.47, for a total value of $245,394.16. Following the sale, the chairman now owns 1,487,350 shares in the company, valued at approximately $9,623,154.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Replimune Group Stock Up 6.5 %

Shares of Replimune Group stock opened at $5.93 on Thursday. The business has a 50-day simple moving average of $7.10 and a 200-day simple moving average of $8.17. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.72 and a quick ratio of 10.72. Replimune Group, Inc. has a one year low of $5.46 and a one year high of $24.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. purchased a new stake in shares of Replimune Group during the 4th quarter worth $41,024,000. Goldman Sachs Group Inc. lifted its holdings in Replimune Group by 300.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock worth $18,874,000 after buying an additional 1,679,553 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after acquiring an additional 699,679 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in shares of Replimune Group during the 4th quarter worth about $2,575,000. Finally, Rafferty Asset Management LLC increased its holdings in shares of Replimune Group by 148.1% in the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock valued at $3,906,000 after acquiring an additional 276,596 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.